Cladribine with or without prednisone in the treatment of previously treated and untreated B-cell chronic lymphocytic leukaemia - Updated results of the multicentre study of 378 patients

British Journal of Haematology

Volumn 108, Issue 2, 2000, Pages 357-368

  Robak, Tadeusz ^k   Blonski J Z ^l   Kasznicki, M ^l   Konopka, L ^a   Ceglarek, B ^a   Dmoszynska A ^b   Soroka Wojtaszko, M ^b   Skotnicki, A B ^c   Nowak, W ^c   Dwilewicz Trojaczek, J ^d   Tomaszewska, A ^d   Hellmann, A ^e   Lewandowski, K ^e   Kuliczkowski, K ^f   Potoczek, S ^f   Zdziarska, B ^g   Hansz, J ^h   Kroll, R ^h   Komarnicki, M ^h   Holowiecki J ⁱ   Grieb, P ^j   more..

^a INSTITUTE OF HEMATOLOGY AND TRANSFUSION MEDICINE   (Poland)

^b MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^c JAGIELLONIAN UNIVERSITY   (Poland)

^d MEDICAL UNIVERSITY OF WARSAW   (Poland)

^e MEDICAL UNIVERSITY OF GDANSK   (Poland)

^f Academy of Medicine   (Poland)

^g POMERANIAN MEDICAL UNIVERSITY   (Poland)

^h POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

ⁱ MEDICAL UNIVERSITY OF SILESIA   (Poland)

^j MOSSAKOWSKI MEDICAL RESEARCH CENTRE   (Poland)

^k MEDICAL UNIVERSITY OF LODZ   (Poland)

^l NONE

more..

Author keywords

Chronic lymphocytic leukaemia; Cladribine; Efficiency; Prednisone; Side effects

Indexed keywords

CLADRIBINE; PREDNISONE;

ADULT; AGED; ARTICLE; CANCER STAGING; CHRONIC LYMPHATIC LEUKEMIA; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; IMMUNOPHENOTYPING; INFECTION; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT OUTCOME;

2-CHLOROADENOSINE; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLADRIBINE; DEOXYADENOSINES; FEMALE; HUMANS; LEUKEMIA, B-CELL, CHRONIC; MALE; MIDDLE AGED; PREDNISONE; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 0034063889     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2000.01850.x     Document Type: Article

References (46)

1. Anaissie, E., Kontoyiannis, D.P., Kantarjian, H., Eltine, L., Robertson, L.E. & Keating, M. (1992) Listeriosis in patients with chronic lymphocytic leukemia who were treated with fludarabine and prednisone. Annals of Internal Medicine, 117, 466-469.
2. Anaissie, E.J., Konotoyiannis, D.P., O'Brien, S., Kantarjian, H., Robertson, L., Lester, S. & Keating, M.J. (1998) Infections in patients with chronic lymphocytic leukemia treated with fludarabine. Annals of Internal Medicine, 129, 559-566.
3. Bergman, I. (1997) Present status of purine analogs in the therapy of chronic lymphocytic leukemias. Leukemia, 11, 534.
4. Betticher, B.C., von Rohr, A., Ratschiller, D., Hsu Schmitz, S.F., Egger, T., Sonderegger, T., Hermann, R., Kroner, T., Zulian, G.B., Cavahi, F., Fey, M.F. & Cerny, T. (1998) Fewer infection but maintained antitumor activity with lower-dose versus standard-dose cladribine in pretreated low grade non-Hodgkin's lymphoma. Journal of Clinical Oncology, 16, 850-858.
5. Binet, J.L. & French Co-operative Group on, C.L.L. (1993) Treatment of chronic lymphocytic leukaemia. Bailliere's Clinical Haematology, 6, 867-885.
6. Brugiatelli, M., Claisse, J.F., Lenormant, B., Marabito, F., Callea, V., Mallaim, K., Chewret, S.J.L., Digniero, G. & Travade, P. (1997) Long term clinical outcome of B-cell chronic lymphocytic leukaemia patients in clinical remission phase evaluated at phenotypic level. British Journal of Haematology, 97, 113-118.
7. Carrera, C.J., Saven, A. & Piro, L.D. (1994) Purine metabolism of lymphocytes. Targets for chemotherapy drug development. Hematology Oncology Clinics of North America, 8, 357-381.
8. Catovsky, D., Fooks, J. & Richards, R. (1989) Prognostic factors in chronic lymphocytic leukaemia: the importance of age, sex and response to treatment and survival. A report from the MRC CLL trial. British Journal of Haematology, 72, 141-149.
9. Catovsky, D. & Murphy, R.L.W. (1995) Key issues in the treatment of chronic lymphocytic leukaemia (CLL). European Journal of Cancer, 31A, 2146-2154.
10. Cheson, B.D. (1998) Therapy for previously untreated chronic lymphocytic leukemia: a reevaluation. Seminars in Hematology, 35, 14-21.
11. Cheson, B.D., Bennet, J.M., Grever, M. & Kay, N. (1996) National Cancer Institute Sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood, 87, 4990-4997.
12. Cheson, B.D., Bennet, J.M., Rai, K.R., Grever, M.R., Kay, N.E., Schiffer, C.A., Oken, M.M., Keating, M.J., Boldt, D.H., Kempin, S.J. & Foon, K.A. (1988) Guidelines for chronic lymphocytic leukemia: recommendations of the National Cancer Institute Sponsored Working Group. American Journal of Hematology, 29, 152-163.
13. Delannoy, A., Martiat, P., Gala, J.L., Deneys, V., Ferrant, A., Bosly, A., Schieff, J.M. & Michaux, J.L. (1995) 2-Chlorodeoxyadenosine (CdA) for patients with previously untreated chronic lymphocytic leukemia (CLL). Leukemia, 9, 1132-1135.
14. Di Raimondo, F., Guistolisi, R., Cacciol, E., Kantarjian, H., Robertson, L.B. & Keating, M.J. (1993) Autoimmune haemolytic anaemia in chronic lymphocytic leukemia patients treated with fludarabine. Leukaemia and Lymphoma, 11, 63-68.
15. Ezdinli, E.Z., Stutzman, L., Williams Aungst, C. & Firat, D. (1969) Corticosteroid therapy for lymphomas and chronic lymphocytic leukemia. Cancer, 23, 300.
16. Han, T., Ezdinli, E.Z., Shimaoka, K. & Desai, D. (1973) Chlorambucil vs. combined chlorambucil - corticosteroid therapy in chronic lymphocytic leukemia. Cancer, 31, 502-508.
17. Itala, M., Vanhatalo, S. & Remes, K. (1997) Recombinat human granulocyte-macrophage colony-stimulating factor (GM-CSF) on chemotherapy induced myelosuppression: a crossover study. Leukemia and Lymphoma, 25, 503-508.
18. Jaksic, B., Brugiatelli, M., Krc, I., Losonczi, H., Holowiecki, J., Planinc-Peraica, A., Kusec, R., Morabito, F., Iacopino, P. & Lutz, D. (1997) High dose chlorambucil versus Binet's modified cyclophosphamide, doxorubicin, vincristine, and prednisone regimen in the treatment of patients with advanced B-cell chronic lymphocytic leukemia. Results of an international multicenter randomized trial. Cancer, 79, 2107-2114.
19. Johnson, S., Smith, A.G., Loffler, H., Osby, E., Juliusson, G., Emmerich, B., Wyld, P.J., Hiddemann, W. & French Cooperative Group on, C.L.L. (1996) Multicenter prospective randomized trial of fludarabine versus cyclophosphamide, doxorubicin and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. Lancet, 377, 1432-1438.
20. Juliusson, G. & Liliemark, J. (1993) High complete remission rate from 2-chloro-2′-deoxyadenosine in previously treated patients with B-cell chronic lymphocytic leukemia: response predicted by rapid decrease of blood lymphocyte count. Journal of Clinical Oncology, 11, 679-689.
21. Juliusson, G., Elmhron-Rosenborg, A. & Liliemark, J. (1992) Response to 2-chlorodeoxyadenosine in patients with B-cell chronic lymphocytic leukemia resistant to fludarabine. New England Journal of Medicine, 327, 1056-1061.
22. Juliusson, G. & Liliemark, J. (1994) Retreatment of chronic lymphocytic leukemia with 2-chlorodeoxyadenosine (CdA) at relapse following CdA-induced remission: no acquired resistance. Leukemia and Lymphoma, 13, 75-80.
23. Juliusson, G. & Liliemark, J. (1996) Long-term survival following cladribine (2-chlorodeoxyadenosine) therapy in previously treated patients with chronic lymphocytic leukemia. Annals of Oncology, 7, 373-379.
24. Kaplan, E.L. & Meier, P. (1958) Nonparametric estimation from incomplete observations. Journal of the American Statistical Association, 53, 457-481.
25. Kazimierczuk, Z., Cottam, H.B., Ravanliar, G.R. & Robins, R.K. (1984) Synthesis of 2′-deoxytubercidin, 2′-deoxyadenosin and related 2′-deoxynucleosides via a novel direct stereospecific serum salt glycosylation procedure. Journal of the American Chemical Society, 106, 6379-6382.
26. Keating, M.J., Kantarjian, H., Talpaz, M., Redman, J., Koller, C., Barlogie, B., Velasquez, W., Plunkett, W., Freireich, E.J. & McKredie, K.B. (1989) Fludarabine: a new agent with major activity against chronic lymphocytic leukemia. Blood, 74, 19-25.
27. Keating, M.J., O'Brien, S., Kantarjian, H., Plunkett, W., Estey, E., Koller, C., Beran, M. & Freireich, E. (1993) Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent. Blood, 81, 2878-2884.
28. Keating, M.J., O'Brien, S., Lerner, C., Koller, C., Beran, M., Robertson, L.E., Freireich, E.J., Estey, E. & Kantarjian, H. (1998) Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood, 92, 1165-1171.
29. Montserrat, E. & Rozman, C. (1993) Chronic lymphocytic leukemia treatment. Blood Reviews, 7, 164-175.
30. O'Brien, S., del Giglio, A. & Keating, M. (1993a) Advances in the biology and treatment of B-cell chronic lymphocytic leukemia. Blood, 85, 307-318.
31. O'Brien, S., Kantarjian, H., Beran, M., Koller, C., Talpaz, M., Lerner, S. & Keating, M.J. (1997) Fludarabine and granulocyte colony-stimulating factor (G-CSF) in patients with chronic lymphocytic leukemia. Leukemia, 11, 1631-1635.
32. O'Brien, S., Kantarjian, H., Beran, M., Smith, T., Koller, C., Estey, E., Robertson, L.E., Lerner, S. & Keating, M. (1993b) Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis - derived prognostic model for response to treatment. Blood, 82, 1690-1700.
33. O'Brien, S., Kantarjian, H., Estey, E., Koller, C., Robertson, B., Beran, M., Andreeff, M., Pierce, S. & Keating, M. (1994) Lack of effect of 2-chlorodeoxyadenosine therapy in patients with chronic lymphocytic leukemia refractory to fludarabine therapy. New England Journal of Medicine, 330, 319-322.
34. Oken, M.M., Creech, R.H., Torney, D.C., Horton, J., Davis, T.E., McFadden, E.T. & Carbone, P.P. (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. American Journal of Clinical Oncology, 5, 649-655.
35. Piro, L.D., Carrera, C.J., Beutler, E. & Carson, D.A. (1989) 2-Chlorodeoxyadenosine: an effective new agent for the treatment of chronic lymphocytic leukemia. Blood, 72, 1069-1073.
36. Rai, K.R., Peters, B., Elias, L., Shephard, J., Hines, J. & Nelson, D. (1996) A randomized comparison of fludarabine and chlorambucil for patients with previously untreated chronic lymphocytic leukemia. A CALGB, SWOG, CTG/NCI-6 and EGOG inter-group study (abstract). Blood, 88 (Suppl. 1), 141.
37. Rai, K.R., Sawitsky, A., Cronkite, E.P., Chanana, A.D., Levy, R. & Pasternack, B.S. (1975) Clinical staging of chronic lymphocytic leukemia. Blood, 46, 219-234.
38. Robak, T., Błasim̀ska-Morawiec, M., Bloǹski, J., Krykowski, E., Dmoszyǹska, A., Skotnicki, A.B., Konopka, L., Hellmann, A., Dwilewicz-Trojaczek, J., Zdziarska, B., Kotlarek-Haus, S. & Maj, S. (1998) Randomized multicenter study of the effectiveness of 2-chlorodeoxyadenosine with prednisone versus chlorambucil with prednisone in previously untreated chronic lymphocytic leukemia (CLL). Blood, 92 (Suppl. 1), 190a (abstract 2021).
39. Robak, T., Blasimska-Morawiec, M., Błoǹski, J.Z., Krykowski, E., Komarnicki, M., Trepiǹska, E., Kazimierczuk, M., Hansz, J., Dmoszyǹska, A., Roliǹski, J., Konopka, L., Skotnicki, A.B., Nowak, W.S., Kotlarek-Haus, S., Zdziarska, B. & Urasim̀ski, I. (1997a) The effect of 2-h infusion of 2-chlorodeoxyadenosine (cladribine) with prednisone in previously untreated B-cell chronic lymphocytic leukemia. European Journal of Cancer, 33, 2347-2351.
40. Robak, T., Błasim̀ska-Morawiec, M., Krykowski, E., Hellmann, A. & Konopka, L. (1997b) Autoimmune haemolytic anaemia in patients with chronic lymphocytic leukaemia treated with 2-chlorodeoxyadenosine (cladribine). European Journal of Haematology, 58, 109-113.
41. Robak, T., Błasim̀ska-Morawiec, M., Krykowski, E., Kasznicki, M., Hansz, J., Komarnicki, M., Konopka, L., Durzyǹski, T., Ceglarek, B., Sikorska, A., Kotlarek-Haus, S., Mazur, M., Urasim̀ski, I., Zdziarska, B., Maj, S., Kopeć, I., Skotnicki, A.B., Dwilewicz-Trojaczek, J., Kuratowska, E. & Grieb, P. (1996) Intermittent 2-hour intravenous infusions of 2-chlorodeoxyadenosine in the treatment of 110 patients with refractory or previously untreated B-cell chronic lymphocytic leukemia. Leukemia and Lymphoma, 22, 509-514.
42. Robertson, L.E., Huh, Y.O., Butler, J.J., Pugh, W.C., Hirsch-Ginsberg, C., Stass, S., Kantarijan, H. & Keating, M.J. (1992) Response assessment in chronic lymphocytic leukemia after fludarabine plus prednisone: clinical, pathologic, immunophenotypic, and molecular analysis. Blood, 80, 29-36.
43. Saven, A., Lemon, R.H., Kosty, M., Beutler, E. & Piro, L.D. (1995) 2-Chlorodeoxyadenosine activity in patients with untreated chronic lymphocytic leukemia. Journal of Clinical Oncology, 13, 570-574.
44. Sawitsky, A., Rai, K.R., Glidewell, O. & Silver, R.T. (1977) Comparison of daily versus intermittent chlorambucil and prednisone therapy in the treatment of patients with chronic lymphocytic leukemia. Blood, 50, 1049-1059.
45. Sorensen, J.M., Vena, D.A., Fallavollita, A., Chun, H.G. & Cheson, B.D. (1997) Treatment of refractory chronic lymphocytic leukemia with fludarabine phosphate via the group C protocol mechanism of the National Cancer Institute: five year follow-up report. Journal of Clinical Oncology, 15, 458-465.
46. Van den Neste, E., Delannoy, A., Vandercam, B., Bosly, A., Ferrant, A., Mineur, P., Montfort, L., Straetmans, N., Filleul, B. & Michaux, J.L. (1996) Infectious complications after 2-chlorodeoxyadenosine therapy. European Journal of Haematology, 56, 235-240.